Physician profile
Hye Kwag
NPI 1306493671
$1,843.99
in general payments reported to CMS, 2019-2025
23 companies · $419 in 2025
The $419 reported for 2025 was more than what 76% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $640 · 2022: $197 · 2023: $220 · 2024: $368 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $912 · Grant: $95.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $911.58 |
| Grant | $95.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $330.13 | 2023-2025 | Micra, Abre |
| Abbott Laboratories | $183.87 | 2024 | Assurity, Diamondback Peripheral |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $155.57 | 2023-2025 | Lifevest |
| Inari Medical, INC. | $126.05 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boston Scientific Corporation | $125.62 | 2022-2025 | General - Structural Heart, Watchman Flx |
| Impulse Dynamics (USA) INC. | $120.11 | 2021-2022 | |
| Akcea Therapeutics, INC. | $119.24 | 2021 | |
| Pfizer INC. | $110.69 | 2021-2022 | |
| Amgen INC. | $89.27 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $80.10 | 2021 | |
| Esperion Therapeutics, INC. | $67.09 | 2021-2025 | Nexletol |
| Amarin Pharma, INC. | $62.12 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.75 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $30.90 | 2021 | |
| Merck Sharp & Dohme LLC | $26.01 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $25.89 | 2021 | |
| Sanofi-Aventis U.S. LLC | $23.49 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.03 | 2024 | |
| Edwards Lifesciences Corporation | $21.27 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $21.02 | 2024 | Camzyos |
| Cvrx, INC. | $20.15 | 2025 | Barostim Neo System |
| Novo Nordisk INC | $17.78 | 2025 | Wegovy |
| Atricure, INC. | $14.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hye Kwag listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.